Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

-7.1%

3:14 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	10/17/2012 4:09:52 PM
	of 13111

Provectus Pharmaceuticals Publishes Patent Application, PV-10 Results Wednesday October 17, 2012 An article appearing on Dermwire, (from the publishers of Practical Dermatology), reports on Provectus's recently published patent application entitled "Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer", as well as the final top-line data from the Phase 2 clinical trial of PV-10 for metastatic melanoma presented at the European Society for Medical Oncology 2012 Congress in Vienna. The article is available on the Dermwire website at: http://bmctoday.net/practicaldermatology/dermwire/view.asp?20121002-provectus_pharmaceuticals_publishes_patent_application

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next